Weight-Loss Injection Demand Puts Swiss Firm Ypsomed Under Pressure to Speed Up Expansion

Simon Michel, a prominent figure in both Swiss politics as an FDP National Councillor and in the business world as CEO of Ypsomed, finds himself navigating a high-stakes race on multiple fronts. His company, a key player in the medical technology sector, is at the forefront of producing injection systems for the burgeoning market of weight-loss drugs, a field experiencing explosive global demand.

The demand for these "slimming injections" necessitates a rapid and significant expansion of manufacturing capabilities. Ypsomed, a leader in this niche, is responding with substantial investments, channeling the majority of its 1.3 billion Swiss franc capital expenditure between 2024 and 2030 into its plant in Schwerin, Germany. Additional production lines have also been established at its facility in Solothurn, Switzerland, underscoring the company's commitment to scaling up operations.

However, the market is intensely competitive. Ypsomed, along with the Zug-based SHL Medical, largely dominates the injection system business. Yet, Ypsomed is currently facing a significant challenge in its expansion efforts within the United States. SHL Medical's strategic move to open a production facility in South Carolina in March 2025 has allowed them to directly supply American pharmaceutical firms, circumventing currency exchange risks and gaining a competitive edge.

This strategic lag in the US market is a critical concern for Ypsomed. While the company's North Carolina facility is expected to be operational by the end of the year, the delay means they are currently behind their primary rival. Michel's dual role highlights the pressure to perform: not only must he champion Switzerland's interests in European policy debates, particularly concerning the "10-Million-Switzerland Initiative" and the crucial bilateral agreements with the EU, but he must also ensure Ypsomed maintains its competitive edge in a rapidly evolving global pharmaceutical supply chain.

“

Simon Michel, the CEO of the Burgdorf-based medical technology company Ypsomed, speaks quickly, in German and English. He has no time to lose, neither in business nor in politics.